These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24875133)

  • 1. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.
    Plimack ER; Desai JR; Issa JP; Jelinek J; Sharma P; Vence LM; Bassett RL; Ilagan JL; Papadopoulos NE; Hwu WJ
    Invest New Drugs; 2014 Oct; 32(5):969-75. PubMed ID: 24875133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
    Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
    J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
    Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
    Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
    [No Abstract]   [Full Text] [Related]  

  • 7. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
    Navid F; Herzog CE; Sandoval J; Daryani VM; Stewart CF; Gattuso J; Mandrell B; Phipps S; Chemaitilly W; Sykes A; Davidoff AM; Shulkin BL; Bahrami A; Furman WL; Mao S; Wu J; Schiff D; Rao B; Pappo A
    Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
    Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
    Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
    J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.
    Schwartsmann G; Schunemann H; Gorini CN; Filho AF; Garbino C; Sabini G; Muse I; DiLeone L; Mans DR
    Invest New Drugs; 2000 Feb; 18(1):83-91. PubMed ID: 10830142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
    Markowitz J; Luedke EA; Grignol VP; Hade EM; Paul BK; Mundy-Bosse BL; Brooks TR; Dao TV; Kondalasula SV; Lesinski GB; Olencki T; Kendra KL; Carson WE
    J Immunother; 2014 Jan; 37(1):55-62. PubMed ID: 24316557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
    Tarhini AA; Cherian J; Moschos SJ; Tawbi HA; Shuai Y; Gooding WE; Sander C; Kirkwood JM
    J Clin Oncol; 2012 Jan; 30(3):322-8. PubMed ID: 22184371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
    Fang F; Balch C; Schilder J; Breen T; Zhang S; Shen C; Li L; Kulesavage C; Snyder AJ; Nephew KP; Matei DE
    Cancer; 2010 Sep; 116(17):4043-53. PubMed ID: 20564122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
    George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
    Eigentler TK; Gutzmer R; Hauschild A; Heinzerling L; Schadendorf D; Nashan D; Hölzle E; Kiecker F; Becker J; Sunderkötter C; Moll I; Richtig E; Pönitzsch I; Pehamberger H; Kaufmann R; Pföhler C; Vogt T; Berking C; Praxmarer M; Garbe C;
    Ann Oncol; 2016 Aug; 27(8):1625-32. PubMed ID: 27287206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
    Mozzillo N; Ascierto P
    Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
    Stathis A; Hotte SJ; Chen EX; Hirte HW; Oza AM; Moretto P; Webster S; Laughlin A; Stayner LA; McGill S; Wang L; Zhang WJ; Espinoza-Delgado I; Holleran JL; Egorin MJ; Siu LL
    Clin Cancer Res; 2011 Mar; 17(6):1582-90. PubMed ID: 21278245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.